Mira Pharmaceuticals appoints fractional CFO after CFO Weichselbaum departs

MIRA PHARMACEUTICALS, INC.

Alan Weichselbaum resigned as CFO effective June 6, 2026, with no disagreement with the company.
Andriy Mushak, CPA with over 20 years SEC experience, appointed fractional CFO effective June 6, 2026.
Mushak will serve via consulting agreement with LMAM Consulting Group; company to pay $6,000 per month.
Mushak's expertise includes SEC reporting, audit readiness, internal controls, and capital-markets support.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andriy Mushak

fractional Chief Financial Officer

MIRA · MIRA PHARMACEUTICALS, INC.

Effective: 2026-06-06
Filed: June 8, 2026, 5:00 PM ET

On June 2, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026 (the “Effective Date”).

Departed

Alan Weichselbaum

Chief Financial Officer

MIRA · MIRA PHARMACEUTICALS, INC.

Effective: 2026-06-06
Successor: Andriy Mushak
Filed: June 8, 2026, 5:00 PM ET

Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Mira Pharmaceuticals, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andriy Mushak was appointed as fractional Chief Financial Officer at MIRA PHARMACEUTICALS, INC..

Action: appointed
Role: fractional Chief Financial Officer

Exact text from the filing

On June 2, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026 (the “Effective Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alan Weichselbaum resigned as Chief Financial Officer at MIRA PHARMACEUTICALS, INC..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Mira Pharmaceuticals, Inc. (the “Company”).

View on SEC.gov

MIRA PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-027751

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.